Answers are grounded in this paper and cite their sources.
We performed a 3-month, double-blind, placebo-controlled trial of 300 mg of gangliosides (Cronassial) in 40 outpatients with amyotrophic lateral sclerosis (ALS). We evaluated drug effect through physical examinations and symptom scales. Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients.
No takes yet. Share an insight, caveat, or question.
Lacomblez et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: